The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biologics Monoclonal Antibodies Drug Market Research Report 2024
Synopsis
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
Global Biologics Monoclonal Antibodies Drug market is projected to reach US$ 470320 million in 2029, increasing from US$ 212750 million in 2022, with the CAGR of 12.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biologics Monoclonal Antibodies Drug market research.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biologics Monoclonal Antibodies Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Sobi
Innovent Biologics
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biologics Monoclonal Antibodies Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
Global Biologics Monoclonal Antibodies Drug market is projected to reach US$ 470320 million in 2029, increasing from US$ 212750 million in 2022, with the CAGR of 12.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biologics Monoclonal Antibodies Drug market research.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biologics Monoclonal Antibodies Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Sobi
Innovent Biologics
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biologics Monoclonal Antibodies Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologics Monoclonal Antibodies Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
1.3 Market by Application
1.3.1 Global Biologics Monoclonal Antibodies Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biologics Monoclonal Antibodies Drug Market Perspective (2018-2029)
2.2 Biologics Monoclonal Antibodies Drug Growth Trends by Region
2.2.1 Global Biologics Monoclonal Antibodies Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biologics Monoclonal Antibodies Drug Historic Market Size by Region (2018-2023)
2.2.3 Biologics Monoclonal Antibodies Drug Forecasted Market Size by Region (2024-2029)
2.3 Biologics Monoclonal Antibodies Drug Market Dynamics
2.3.1 Biologics Monoclonal Antibodies Drug Industry Trends
2.3.2 Biologics Monoclonal Antibodies Drug Market Drivers
2.3.3 Biologics Monoclonal Antibodies Drug Market Challenges
2.3.4 Biologics Monoclonal Antibodies Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologics Monoclonal Antibodies Drug Players by Revenue
3.1.1 Global Top Biologics Monoclonal Antibodies Drug Players by Revenue (2018-2023)
3.1.2 Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Players (2018-2023)
3.2 Global Biologics Monoclonal Antibodies Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biologics Monoclonal Antibodies Drug Revenue
3.4 Global Biologics Monoclonal Antibodies Drug Market Concentration Ratio
3.4.1 Global Biologics Monoclonal Antibodies Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologics Monoclonal Antibodies Drug Revenue in 2022
3.5 Biologics Monoclonal Antibodies Drug Key Players Head office and Area Served
3.6 Key Players Biologics Monoclonal Antibodies Drug Product Solution and Service
3.7 Date of Enter into Biologics Monoclonal Antibodies Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologics Monoclonal Antibodies Drug Breakdown Data by Type
4.1 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Type (2018-2023)
4.2 Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Type (2024-2029)
5 Biologics Monoclonal Antibodies Drug Breakdown Data by Application
5.1 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Application (2018-2023)
5.2 Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
6.2 North America Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2023)
6.4 North America Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
7.2 Europe Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2023)
7.4 Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
8.2 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
9.2 Latin America Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2023)
9.4 Latin America Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
10.2 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Biologics Monoclonal Antibodies Drug Introduction
11.1.4 Roche Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Biologics Monoclonal Antibodies Drug Introduction
11.2.4 Amgen Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Biologics Monoclonal Antibodies Drug Introduction
11.3.4 AbbVie Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biologics Monoclonal Antibodies Drug Introduction
11.4.4 Sanofi Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biologics Monoclonal Antibodies Drug Introduction
11.5.4 Johnson & Johnson Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Biologics Monoclonal Antibodies Drug Introduction
11.6.4 Pfizer Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Detail
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Biologics Monoclonal Antibodies Drug Introduction
11.7.4 Eli Lilly Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.7.5 Eli Lilly Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Biologics Monoclonal Antibodies Drug Introduction
11.8.4 Novartis Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.8.5 Novartis Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck Biologics Monoclonal Antibodies Drug Introduction
11.9.4 Merck Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.9.5 Merck Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Biologics Monoclonal Antibodies Drug Introduction
11.10.4 Biogen Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.10.5 Biogen Recent Development
11.11 Sobi
11.11.1 Sobi Company Detail
11.11.2 Sobi Business Overview
11.11.3 Sobi Biologics Monoclonal Antibodies Drug Introduction
11.11.4 Sobi Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.11.5 Sobi Recent Development
11.12 Innovent Biologics
11.12.1 Innovent Biologics Company Detail
11.12.2 Innovent Biologics Business Overview
11.12.3 Innovent Biologics Biologics Monoclonal Antibodies Drug Introduction
11.12.4 Innovent Biologics Revenue in Biologics Monoclonal Antibodies Drug Business (2018-2023)
11.12.5 Innovent Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
